by Kazeem Olalekan
A safety alert has come to our attention via the MHRA: Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended.
Teva levothyroxine 100 microgram tablets will cease to be available in the UK within the next few weeks, and no further supplies of this product will be released for marketing.
Advice for healthcare professionals:
- Prescribers should be alert to the possibility that a change in a patient’s symptoms and TSH status may be attributed to switching to Teva product from another levothyroxine product
- Certain patient groups such as pregnant women, patients with heart disease, and patients receiving treatment with levothyroxine following treatment for thyroid cancer should be monitored closely. If taking Teva tablets, they should have an early appointment with their doctor for a clinical review and blood test
- The majority of patients will be able to continue with their medication and change to a different levothyroxine product at their next prescription
- Patients who experience a significant change in symptoms especially after switching should have their TSH status reviewed and their dose of levothyroxine adjusted accordingly
- You can report suspected lack of efficacy on a Yellow Card (www.mhra.gov.uk/yellowcard)
Time to review your stock levels!